RxDoctor Payments Data

Jon-Michael Allen, PA

Medical · Kilauea, HINPI 1477976892

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 37.8% of the total.

$1,209in general payments, 2019–2025

Across 64 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$457
  • Pfizer$171
  • GSK$135
  • AstraZeneca$69
  • Novo Nordisk$64
  • Takeda Pharmaceuticals U.S.A., Inc.$62
  • plus $251 from 7 others

What the payments were for

  • Food & beverage$1,209100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,209 in reported general payments places this provider in the 65th percentile of 63 medical providers in Hawaii.

See all medical providers in Hawaii

Medicare billing

Part B allowed, 2024
$93,949
Medicare patients
261
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban86$102,106
OzempicSemaglutide57$74,191
JardianceEmpagliflozin38$47,087
EliquisApixaban46$40,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$35,517
BriviactBrivaracetam15$23,567
MyrbetriqMirabegron16$22,434
EntrestoSacubitril/Valsartan20$22,183
FarxigaDapagliflozin Propanediol16$20,241
VascepaIcosapent Ethyl19$13,867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen232$5,729
Atorvastatin Calcium358$4,968
Losartan Potassium289$3,374
Rosuvastatin Calcium134$2,750
Metoprolol Succinate220$2,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$64$74,19157 claims
PfizerEliquis$171$40,16046 claims
GSKTrelegy Ellipta$135$35,51749 claims
AstraZenecaFarxiga$69$20,24116 claims
AbbVieSynthroid, Armour Thyroid$457$2,66933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 63 medical providers in Hawaii.

Other medical in Kilauea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →